NCT05899582 Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial
| NCT ID | NCT05899582 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Symptomatic Chronic Middle Cerebral Artery Occlusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 420 participants |
| Start Date | 2023-09-15 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 420 participants in total. It began in 2023-09-15 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CMOSS-2 trial is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit symptomatic chronic occlusion of the middle cerebral artery in patients with severe hemodynamic insufficiency. Only high-volume center with a proven track record will be included. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus bypass surgery. Primary outcome is ischemic stroke in the territory of the target artery within 24 months after randomization.
Eligibility Criteria
Inclusion Criteria: 1. Age of 18-65 years; 2. Confirmed as chronic occlusion of unilateral middle cerebral artery (MCA) by digital subtraction angiography (DSA) or computed tomography angiography (CTA). Other cerebral artery stenosis should be less than 50%. 3. CT perfusion demonstrates severe hemodynamic insufficiency in the territory of the qualifying MCA with MTT (symptomatic side) ≥ 6s or rCBF (symptomatic side/contralateral side) ≤ 0.8; 4. mRS score is 0-2 points; 5. A history of ischemic events (including\<1/2 cerebral infarction in the middle cerebral artery supply area, or transient ischemic attack \[TIA\]) related to the qualifying artery within 12 months ; 6. The onset of acute stroke should be more than 1 month; 7. CT or MRI excludes large cerebral infarction (infarction\>1/2 of the territory of the qualifying middle cerebral artery); 8. Patients or their guardians voluntarily participate of the study and sign the consent form. Exclusion Criteria: 1. History of intracranial hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or extradural hemorrhage within 6 weeks; 2. Unstable angina pectoris or myocardial infarction, congestive heart failure within 6 months; 3. Women who are pregnant or lactating; 4. Coagulation dysfunction or hemorrhagic tendency (e.g. INR \> 1.5 and/or platelet count \< 100,000 mcL); 5. Other diseases with a life expectancy of less than 2 years 6. Previous treatment with EC-IC bypass surgery 7. Known allergy or contraindication to aspirin or clopidogrel or other antiplatelet drugs. 8. Known cardiac conditions that may lead to cardiogenic embolism: including prosthetic valves, infective endocarditis, left atrial or left ventricular thrombosis, atrial fibrillation, sick sinus node syndrome, atrial mucinous tumor or cardiomyopathy, ejection fraction \<25%; 9. Allergy to iodine or x-ray contrast, blood creatinine \> 3.0 mg/dl or other contraindications to arteriography 10. Uncontrolled diabetes mellitus with fasting blood sugar (FBS) \>16.7 mmol/L 11. Uncontrolled hypertension with a sitting systolic blood pressure \>180 mmHg or a sitting diastolic blood pressure \>110 mmHg; 12. Persistent worsening of neurological symptoms within 72 hours; 13. Severe liver dysfunction, defined as serum alanine transaminase (ALT) and/or glutamic oxalacetic transaminase (AST) \> 3 times the upper limit of normal range; 14. Active peptic ulcer disease; 15. Having received a clinical trial drug or device within 30 days prior to screening, or being enrolled in another clinical trial; 16. Other diseases or medical history that, in the judgment of the investigator, may affect the efficacy or safety evaluation of this study.
Contact & Investigator
Liqun Jiao, MD
PRINCIPAL INVESTIGATOR
Xuanwu Hospital, Beijing
Frequently Asked Questions
Who can join the NCT05899582 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Symptomatic Chronic Middle Cerebral Artery Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05899582 currently recruiting?
Yes, NCT05899582 is actively recruiting participants. Contact the research team at leavesyan@sina.com for enrollment information.
Where is the NCT05899582 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05899582 clinical trial?
NCT05899582 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Liqun Jiao, MD at Xuanwu Hospital, Beijing. The trial plans to enroll 420 participants.